Navigation Links
Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting

NEW YORK, Dec. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will hold its Annual Shareholders' Meeting (the "Meeting") on Monday, December 23, 2013 at 9:30 AM ET at the Sheraton Mahwah, 1 International Boulevard, Mahwah, NJ.

The Meeting will include an introduction, adjournment and Company overview provided by Kaushik J. Dave, President and Chief Executive Officer of Actinium.

The Proxy Statement, with the accompanying Notice of Annual Meeting, and 2012 Annual Report on Form 10–K are available on the "Investors" section of the Company's website at

Shareholders of record of the Company's common stock at the close of business on November 7, 2013 will be entitled to receive notice of and to vote on matters discussed at the Meeting.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site


Dennis S. Dobson Jr.
Tel: (203) 258-0159

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
2. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
3. Avanir Pharmaceuticals to Participate in Two Conferences in December
4. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
5. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
6. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
7. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
8. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
9. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
10. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
11. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 Celemics, a global ... into the North American market with the establishment of ... and Europe , has secured ... Target Enrichment methodology and sample preparation for DNA sequencing ... both hereditary and somatic genetic testing more accurately, quickly, ...
(Date:10/8/2015)... Global Biologics and Biosimilars ... Biosimilars industry . --> Big Market ... Industry 2015 Deep Market Research Report, Size, Share, ... and depth research report on Global Biologics ... , --> ) , ...
(Date:10/8/2015)... Oct. 8, 2015  Today, DuPont and Caribou ... genome editing, jointly announced a strategic alliance. As ... their respective patent portfolios, with DuPont receiving exclusive ... major row crops, and non-exclusive rights in other ... --> --> In addition, ...
(Date:10/8/2015)... Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical ... autologous cell therapies, today announced its schedule of upcoming presentations ... month of October: Stem Cell Meeting on ... presenting at the annual Partnering Forum, part of the ... October 7-9 in La Jolla, California ...
Breaking Biology Technology:
... form of skin cancer, afflicts more than 50,000 people in ... rise. In a study published online in Genome ... ever before into the RNA world of the melanoma tumor ... the disease. The latest high-throughput DNA sequencing ...
... ... ... ... ...
... ... report on Fermenters market. The US market for fermenters is projected to reach $180 million ... biological drugs worldwide, and growing use of disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- ...
Cached Biology Technology:
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
Breaking Biology News(10 mins):
... that the clouded leopard found on the islands of Borneo ... secretive rainforest animal was originally thought to be the same ... , Genetic analysis conducted at the U.S. National Cancer ... species is comparable to the differences between other large cat ...
... Professor of Medicine and Pharmacology at the University of ... about 265 twin pairs over the past few years, ... "By studying many traits and genes, we have started ... Studying genetic variations in twins provides scientists with data ...
... in stem cell research may mean big things for cancer ... research team at the University of Kentucky published their findings ... The researchers genetically mapped a stem cell gene and its ... investigation all the way through to the identification of the ...
Cached Biology News:
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... The GenElute Gel Extraction Kit combines silica- binding ... vacuum column format. DNA fragments of interest are ... solubilizing the gel. The Gel Solubilization Solution can ... in either TBE or TAE buffer. Extracted DNA ...
... are designed for the rapid purification of linear ... gels. The DNA band is excised from an,agarose ... within the base of the column are a ... and impurities back while allowing DNA to selectively ...
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
Biology Products: